Sleuth Insights

Sleuth Insights (branded "Sleuth") is a San Francisco-based software company serving biopharma strategy, business development and investment teams. Its platform is built on a proprietary biopharma knowledge graph that maps more than a billion relationships across drugs, clinical trials, targets, companies, patents and deals, and that reasons across those connections to answer strategic questions covering biology, clinical evidence, competitive dynamics and deal history. The stated aim is to compress work that would otherwise take weeks or months of analyst or consultant time into hours, and to keep the resulting analyses updated as new readouts, deals and regulatory actions arrive.

Coverage spans structured and unstructured sources: the platform reports 100K+ drugs, 1M+ trials from 20+ international registries, 500K+ biological targets, 80K+ companies, 5M+ news items and press releases, 300K+ US, European, Japanese and Chinese patent filings, 2M+ corporate documents (SEC 10-K, 10-Q and 8-K filings, earnings transcripts, investor presentations), 500K+ sell-side research notes from dozens of brokerages, 70M+ publications and 18,000+ China programs drawn from Mandarin-language sources such as CDE filings, trial registries, patent offices and WeChat. Many sources refresh daily. Every output traces back to an inspectable source document with confidence levels, and the company states that customer prompts, uploads and queries are processed in isolated environments, encrypted in transit and at rest, not used for model training, with development and operations built to SOC 2 standards.

The product is delivered in two main modes plus an API: Sleuth Studio, a self-serve analytical workspace where teams build bespoke datasets, structured analyses and frameworks; and Sleuth Concierge, a dedicated strategic team that scopes questions, pressure-tests hypotheses and produces board-ready deliverables. The company also publishes original research through its Intelligence Hub — competitive landscapes, deal-flow analyses, clinical readout reviews, portfolio and market-access studies across oncology, I&I, metabolic/endocrine, CNS, cardiovascular, respiratory, rare disease and China biopharma — and offers downloadable PDF market maps and landscape graphics behind an email signup.

Founding story

Founded in 2023 by Andrew Pannu, a biopharma analyst who set out to apply machine learning to biotech data analysis, a process he viewed as manual and error-prone relative to the size of the investment and development decisions it informs. He joined venture studio Near Horizon in July 2023, which worked with him on customer research (80+ potential-customer interviews that reshaped the strategy), explored roughly 30 product directions, developed novel mathematical methods that became a patent-pending technology, and built the first version of the product's AI processing systems and web interface.

Business model

B2B enterprise software and services. Access is sold via subscription, with clients engaging through annual retainers for platform access, customized analyses and tailored reports; the website routes prospects to a booked demo where Studio, Concierge and API configurations are matched to company stage.

Subscription-based recurring revenue from annual client retainers covering platform access plus bespoke analyses and reports; pricing is not disclosed publicly.

Traction

Named enterprise and biotech references include Daiichi Sankyo and Epana Bio, both with published case studies. The company maintains an extensive library of original analyses dating from late 2022 through Q3 2026 and a downloads library of roughly 65 report and market-map PDFs. Near Horizon reports helping the founder acquire the company's first customer and close its seed round.

Latest developments

Preqin records a USD 7.68 million seed round led by Bison Ventures in September 2025, with proceeds earmarked for building and scaling the biopharma intelligence platform and expanding the product development and analysis team. A Regulation D notice reported by intelligence360 covers an offering of up to $7,914,999. The most recent published outputs include Q3 2026 intelligence reports on I&I (~15.4K active programs, $325B in M&A since 2021), GLP-1/metabolic and ADCs, plus analyses of Eli Lilly's 26 deals in 2026 and AI infrastructure deployments in biopharma.